Evidence map›Paper›PMID 23255111›Full record

ArticleCell cycle (Georgetown, Tex.)2013

Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations.

Mohamed Jemaà, Lorenzo Galluzzi, Oliver Kepp, Maria Castedo, Santiago Rello-Varona, Ilio Vitale, Guido Kroemer

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. MPS1 inhibition as an anticancer strategy: where do we stand?Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2026
    Review
  2. Article
  3. Article
  4. A New Method for Chromosomes Preparation by ATP-Competitive Inhibitor SP600125Frontiers in bioengineering and biotechnology · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mohamed JemaàInstitut Gustave Roussy, Villejuif, France.
Lorenzo Galluzzi
Oliver Kepp
Maria Castedo
Santiago Rello-Varona
Ilio Vitale
Guido Kroemer
Inserm · FRSorbonne Paris Cité · FRUniversité Paris Cité · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The illicit generation of tetraploid cells constitutes a prominent driver of oncogenesis, as it often precedes the development of aneuploidy and genomic instability. In addition, tetraploid (pre-)malignant cells display an elevated resistance against radio- and chemotherapy. Here, we report a strategy to preferentially kill tetraploid tumor cells based on the broad-spectrum kinase inhibitor SP600125. Live videomicroscopy revealed that SP600125 affects the execution of mitosis, impedes proper cell division and/or activates apoptosis in near-to-tetraploid, though less so in parental, cancer cells. We propose a novel graphical model to quantify the differential response of diploid and tetraploid cells to mitotic perturbators, including SP600125, which we baptized "transgenerational cell fate profiling." We speculate that this representation constitutes a valid alternative to classical "single-cell fate" and "genealogical" profiling and, hence, may facilitate the analysis of cell fate within a heterogeneous population as well as the visual examination of cell cycle alterations.

Indexed as

AnthracenesApoptosisCell Cycle CheckpointsCell Line, TumorDiploidyHCT116 CellsHumansMicroscopy, VideoProtein Kinase InhibitorsTetraploidyTumor Suppressor Protein p53AnthracenesProtein Kinase InhibitorspyrazolanthroneTumor Suppressor Protein p53

Identifiers

PMID23255111
PMCPMC3570510
OpenAlexW1992268707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.